Outlook Therapeutics Inc. Company Profile
NASDAQ: OTLKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 12:21 PM ET
Outlook Therapeutics at a glance
Outlook Therapeutics Inc. (NASDAQ: OTLK) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Iselin, NJ. Outlook Therapeutics is led by Mr. Robert Charles Jahr and employs about 17 people. The company's shares have traded publicly since 2016.
At a market capitalization of $137.3 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001649989, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Outlook Therapeutics do?
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Business description based on the company's public filings.
Company information
- Legal name
- Outlook Therapeutics Inc.
- Ticker
- NASDAQ: OTLK
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Robert Charles Jahr
- Employees
- 17
- Headquarters
- 111 S. Wood Avenue, Iselin, NJ, United States
- Phone
- 609 619 3990
- Website
- outlooktherapeutics.com
- IPO year
- 2016
- Market cap
- $137.30M
- SEC CIK
- 0001649989
Companies similar to Outlook Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AVXLAnavex Life Sciences Corp. | 1.44 | -6.21% | $133.89M | vs OTLK |
| ARMPArmata Pharmaceuticals Inc. | 3.81 | -1.30% | $141.66M | vs OTLK |
| MOLNMolecular Partners AG ADR | 3.74 | -1.84% | $143.26M | vs OTLK |
| VYGRVoyager Therapeutics Inc. | 2.43 | +2.53% | $149.73M | vs OTLK |
| TNYATenaya Therapeutics Inc. | 0.5529 | +1.60% | $123.98M | vs OTLK |
| ABOSAcumen Pharmaceuticals Inc. | 2.12 | +0.95% | $153.31M | vs OTLK |
| ENGNenGene Therapeutics Inc. | 1.77 | -0.63% | $118.54M | vs OTLK |
| CRDLCardiol Therapeutics Inc. Class A | 1.29 | -1.15% | $156.14M | vs OTLK |